This content is from: Features

How to enter the Russian pharmaceutical market

The emergence of big domestic drug companies is reshaping Russia’s pharmaceutical patent landscape. Mikhail Khmara and Yana Lipatova of ARS-Patent explain how originator and generic companies can navigate the country’s changing IP rules

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here

Instant access to all of our content. Membership Options | 30 Day Trial